HK1149717A1 - Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases - Google Patents

Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases

Info

Publication number: HK1149717A1
Authority: HK; Hong Kong
Prior art keywords: prevention; treatment; pharmaceutical composition; osteoarticular diseases; acute
Prior art date: 2008-02-15

Application number

HK11104036.5A

Other languages

English (en)

Inventor

Enrico Bastianelli

Pierre Attali

Chris Vervaet

Original Assignee

Bone Therapeutics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-15

Filing date

2011-04-20

Publication date

2011-10-14

2008-02-15 Priority claimed from EP08101682A external-priority patent/EP2090307A1/en

2011-04-20 Application filed by Bone Therapeutics filed Critical Bone Therapeutics

2011-10-14 Publication of HK1149717A1 publication Critical patent/HK1149717A1/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/281—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
- A61M5/283—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule by telescoping of ampoules or carpules with the syringe body
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Biotechnology (AREA)
Virology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

HK11104036.5A 2008-02-15 2011-04-20 Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases HK1149717A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08101682A EP2090307A1 (en)	2008-02-15	2008-02-15	Pharmaceutical composition for the treatment or prevention of osteoarticular diseases
EP08158285		2008-06-13
PCT/EP2009/051739 WO2009101194A1 (en)	2008-02-15	2009-02-13	Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases

Publications (1)

Publication Number	Publication Date
HK1149717A1 true HK1149717A1 (en)	2011-10-14

Family

ID=40550545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK11104036.5A HK1149717A1 (en)	2008-02-15	2011-04-20	Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases

Country Status (16)

Country	Link
US (3)	US20100285134A1 (pt)
EP (1)	EP2252290B1 (pt)
JP (2)	JP2011512345A (pt)
KR (2)	KR101784642B1 (pt)
CN (1)	CN101878029B (pt)
AU (1)	AU2009214028B2 (pt)
BR (1)	BRPI0905369C8 (pt)
CA (1)	CA2703866C (pt)
DK (1)	DK2252290T3 (pt)
ES (1)	ES2658354T3 (pt)
HK (1)	HK1149717A1 (pt)
IL (1)	IL206080A (pt)
NO (1)	NO2252290T3 (pt)
PL (1)	PL2252290T3 (pt)
PT (1)	PT2252290T (pt)
WO (1)	WO2009101194A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2252290T3 (pl) *	2008-02-15	2018-06-29	Bone Therapeutics S.A.	Kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu chorobom kostno-stawowym
EP2455097B1 (en)	2009-07-16	2016-02-17	Sunstar Inc.	Proteoglycan-containing material
US8394800B2 (en)	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
JP6071558B2 (ja)	2011-01-19	2017-02-01	国立大学法人弘前大学	プロテオグリカンの大量調製法
WO2013076162A1 (en) *	2011-11-21	2013-05-30	Université Libre de Bruxelles	Formulations useful in the treatment of osteoarticular diseases
WO2013076160A1 (en) *	2011-11-21	2013-05-30	Université Libre de Bruxelles	Sustained release formulations useful in the treatment of diseases
SG10201700525PA (en) *	2012-07-25	2017-02-27	Univ Hirosaki	Composition for preventing or treating osteoarthritis
WO2016014408A1 (en)	2014-07-21	2016-01-28	Board Of Regents, The University Of Texas System	Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same
CN105232453B (zh) *	2015-10-30	2018-11-06	上海昊海生物科技股份有限公司	关节腔用***几丁糖纳米注射液及其制备方法
BR112019013503A2 (pt)	2016-12-31	2020-01-07	Bioxcel Therapeutics, Inc.	Uso de dexmedetomidina sublingual para o tratamento da agitação
WO2019063320A1 (en) *	2017-09-27	2019-04-04	Universita' Degli Studi Di Padova	COMPOSITION COMPRISING A BACTERICIDE / PERMEABILITY INCREASING PROTEIN AND HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES
IT201700108102A1 (it) *	2017-09-27	2019-03-27	Univ Degli Studi Padova	Composizione di bactericidal/permeability increasing protein e acido ialuronico per il trattamento delle artropatie
KR102437993B1 (ko)	2018-06-26	2022-08-29	히사미쓰 세이야꾸 가부시키가이샤	마이크로 니들 디바이스 및 그것을 제조하는 방법
CN114983981A (zh)	2018-06-27	2022-09-02	比奥克斯塞尔医疗股份有限公司	含右美托咪定的膜制剂及其制造方法
CA3145388A1 (en)	2019-07-19	2021-01-28	Bioxcel Therapeutics, Inc.	Non-sedating dexmedetomidine treatment regimens
IT202200004574A1 (it)	2022-03-10	2023-09-10	Sergio Ammendola	Nanoparticelle di N-acetilglucosammina e loro applicazioni
US11622949B1 (en)	2022-08-04	2023-04-11	Gad M. Gilad	Agmatine compositions for treatment of osteoarthritis
US11806334B1 (en)	2023-01-12	2023-11-07	Bioxcel Therapeutics, Inc.	Non-sedating dexmedetomidine treatment regimens

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5906934A (en) *	1995-03-14	1999-05-25	Morphogen Pharmaceuticals, Inc.	Mesenchymal stem cells for cartilage repair
US5869041A (en) *	1996-01-12	1999-02-09	The Miriam Hospital	Delivery of bioactive compounds to an organism
ATE203157T1 (de) *	1996-12-20	2001-08-15	Alza Corp	Injizierbare depotgelzubereitung und herstellungsverfahren
US6248345B1 (en) *	1997-07-02	2001-06-19	Euro-Celtique, S.A.	Prolonged anesthesia in joints and body spaces
CA2301018C (en) *	1997-08-22	2006-06-20	Denki Kagaku Kogyo Kabushiki Kaisha	Hyaluronic acid gel, method of its production and medical material containing it
AU6056299A (en)	1998-09-21	2000-04-10	Musc Foundation For Research Development	Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them
AU2001257236B2 (en) *	2000-04-25	2006-03-09	Mesoblast International Sarl	Joint repair using mesenchymal stem cells
JP4927298B2 (ja) *	2000-07-14	2012-05-09	アラーガン、インコーポレイテッド	α−２−アドレナリンアゴニスト成分を含有する組成物
DE10053053A1 (de) *	2000-10-19	2002-05-16	Knoell Hans Forschung Ev	Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
US20030022926A1 (en) *	2001-05-07	2003-01-30	Lavand'homme Patricia	Method for treating neuropathic pain and pharmaceutical preparation therefor
EP1406571A4 (en) *	2001-06-25	2007-05-30	Depuy Int Ltd	LIPOSOMAL ENCAPSULATION OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF ARTHROSIS JOINTS
US7345065B2 (en) *	2002-05-21	2008-03-18	Allergan, Inc.	Methods and compositions for alleviating pain
US20070042951A1 (en) *	2003-10-08	2007-02-22	Allergan, Inc.	Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
JP2007509985A (ja) *	2003-10-31	2007-04-19	ニューロジェン・コーポレーション	カプサイシン受容体作動薬
WO2006039704A2 (en)	2004-09-30	2006-04-13	Janssen Pharmaceutica, N.V.	Pharmaceutical composition and method for treating a joint capsule arthropathy
US20080275129A1 (en) *	2005-03-04	2008-11-06	Acure Pharma Ab	Methods and Pharmaceutical Compositions for the Treatment of Neurological Damage
AU2006311577B2 (en) *	2005-11-09	2013-02-07	Zalicus Inc.	Methods, compositions, and kits for the treatment of medical conditions
ITPD20060219A1 (it) *	2006-05-31	2007-12-01	Fidia Farmaceutici	Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
PL2252290T3 (pl) *	2008-02-15	2018-06-29	Bone Therapeutics S.A.	Kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu chorobom kostno-stawowym

2009
- 2009-02-13 PL PL09710250T patent/PL2252290T3/pl unknown
- 2009-02-13 DK DK09710250.3T patent/DK2252290T3/en active
- 2009-02-13 NO NO09710250A patent/NO2252290T3/no unknown
- 2009-02-13 PT PT97102503T patent/PT2252290T/pt unknown
- 2009-02-13 US US12/811,665 patent/US20100285134A1/en not_active Abandoned
- 2009-02-13 CA CA2703866A patent/CA2703866C/en active Active
- 2009-02-13 AU AU2009214028A patent/AU2009214028B2/en active Active
- 2009-02-13 JP JP2010546354A patent/JP2011512345A/ja active Pending
- 2009-02-13 WO PCT/EP2009/051739 patent/WO2009101194A1/en active Application Filing
- 2009-02-13 KR KR1020167013799A patent/KR101784642B1/ko active IP Right Grant
- 2009-02-13 ES ES09710250.3T patent/ES2658354T3/es active Active
- 2009-02-13 KR KR1020107011867A patent/KR101669682B1/ko active IP Right Grant
- 2009-02-13 BR BRPI0905369A patent/BRPI0905369C8/pt active IP Right Grant
- 2009-02-13 CN CN2009801011744A patent/CN101878029B/zh active Active
- 2009-02-13 EP EP09710250.3A patent/EP2252290B1/en active Active
2010
- 2010-05-30 IL IL206080A patent/IL206080A/en active IP Right Grant
2011
- 2011-04-20 HK HK11104036.5A patent/HK1149717A1/xx unknown
2012
- 2012-09-24 US US13/625,601 patent/US9446065B2/en active Active
2016
- 2016-08-22 JP JP2016161747A patent/JP6352995B2/ja active Active
- 2016-09-19 US US15/269,216 patent/US9872876B2/en active Active

Also Published As

Publication number	Publication date
JP2011512345A (ja)	2011-04-21
KR101669682B1 (ko)	2016-10-27
BRPI0905369C1 (pt)	2020-11-17
PT2252290T (pt)	2018-02-14
AU2009214028B2 (en)	2014-06-12
JP6352995B2 (ja)	2018-07-04
CN101878029A (zh)	2010-11-03
WO2009101194A1 (en)	2009-08-20
BRPI0905369A2 (pt)	2015-06-30
EP2252290A1 (en)	2010-11-24
US20170056434A1 (en)	2017-03-02
KR20160065988A (ko)	2016-06-09
CA2703866C (en)	2016-11-29
CN101878029B (zh)	2013-04-03
EP2252290B1 (en)	2017-11-29
US9872876B2 (en)	2018-01-23
BRPI0905369C8 (pt)	2021-05-25
AU2009214028A1 (en)	2009-08-20
KR101784642B1 (ko)	2017-10-11
US9446065B2 (en)	2016-09-20
BRPI0905369B8 (pt)	2020-02-04
US20130084268A1 (en)	2013-04-04
US20100285134A1 (en)	2010-11-11
CA2703866A1 (en)	2009-08-20
BRPI0905369B1 (pt)	2019-04-24
IL206080A0 (en)	2010-11-30
PL2252290T3 (pl)	2018-06-29
KR20100134548A (ko)	2010-12-23
IL206080A (en)	2016-11-30
NO2252290T3 (pt)	2018-04-28
DK2252290T3 (en)	2018-03-05
JP2016196510A (ja)	2016-11-24
ES2658354T3 (es)	2018-03-09

Publication	Publication Date	Title
HK1149717A1 (en)	2011-10-14	Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
HN2008001720A (es)	2009-06-10	Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
CL2016002589A1 (es)	2017-05-19	Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CL2007001435A1 (es)	2008-01-25	Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
CL2008002369A1 (es)	2009-07-17	Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2012000702A1 (es)	2012-09-14	Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
CL2008001633A1 (es)	2008-12-12	Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
NO20081592L (no)	2008-05-23	Dipeptidylpeptidaseinhibitorer for behandling av diabetes
CL2007003520A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
MX2009007254A (es)	2009-08-12	Composiciones de tableta en tableta.
CL2008003798A1 (es)	2009-10-09	Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
CL2012000163A1 (es)	2012-07-13	Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
PT2222669E (pt)	2013-10-28	Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
CL2009000447A1 (es)	2010-01-04	Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
TW200740799A (en)	2007-11-01	Alpha2C adrenoreceptor agonists
WO2008028965A3 (en)	2008-06-19	Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
CL2007001724A1 (es)	2008-05-09	Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
UA97795C2 (uk)	2012-03-26	Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
CL2007002890A1 (es)	2008-01-18	Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
CL2009000964A1 (es)	2010-03-26	Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
BRPI0816798A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
CL2007003643A1 (es)	2008-03-24	Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2008002082A1 (es)	2009-01-02	Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
CL2007003251A1 (es)	2009-08-07	Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.